Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn’s disease treatment

News Medical

Center

Mixed Factuality

Other: Ian Birkby

Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn’s disease treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing Authorization Application for TREMFYA® (guselkumab) to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.